{"id":"cm082-combined-with-everolimus","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CM082 inhibits receptor tyrosine kinases involved in angiogenesis and tumor cell proliferation, while everolimus blocks mTOR signaling to suppress cell growth and survival. The combination targets both growth factor signaling and metabolic pathways to enhance anti-tumor efficacy.","oneSentence":"CM082 is a tyrosine kinase inhibitor that targets multiple kinases including VEGFR and FLT3, combined with everolimus (an mTOR inhibitor) to provide dual pathway inhibition for cancer treatment.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:10.233Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Renal cell carcinoma"},{"name":"Other solid tumors (under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT03095040","phase":"PHASE3","title":"CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"AnewPharma","startDate":"2016-12-16","conditions":"Renal Cell Cancer Metastatic","enrollment":390},{"nctId":"NCT02577458","phase":"PHASE1","title":"Study of the Combination of CM082 With Everolimus in Patients With mRCC","status":"UNKNOWN","sponsor":"AnewPharma","startDate":"2015-09","conditions":"Renal Cell Carcinoma Recurrent","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["X-82","Affinitor"],"phase":"phase_3","status":"active","brandName":"CM082 combined with everolimus","genericName":"CM082 combined with everolimus","companyName":"AnewPharma","companyId":"anewpharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CM082 is a tyrosine kinase inhibitor that targets multiple kinases including VEGFR and FLT3, combined with everolimus (an mTOR inhibitor) to provide dual pathway inhibition for cancer treatment. Used for Renal cell carcinoma, Other solid tumors (under investigation in Phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}